AstraZeneca Reports Poor Test Results
527141
LONDON - Drug manufacturer AstraZeneca PLC announced Friday that trials of its new lung cancer drug found it didn&#39;t help patients live longer.
115547
AstraZeneca Plc's experimental cancer  drug AZD2281 has been given orphan drug status by the European  Medicines Agency for treating women with ovarian cancer,  Britain's second biggest drugmaker said on Tuesday.
512456
NEW YORK, September 9 (New Ratings) - The FDA has raised questions regarding AstraZenecaâs (AZN.NYS) blood thinner, Exanta. The leading pharmaceutical companyâs hopes had been pinned on Exanta, which
619980
Leading London shares closed lower as drugmaker AstraZeneca suffered a heavy blow following a negative EU ruling on one of its patents.
519169
LONDON (CBS.MW) -- Pharmaceutical giant AstraZeneca shares rose as it said earnings and sales both increased for the third quarter.
180591
Shares of AstraZeneca Plc and GlaxoSmithKline Plc, the UK&#39;s two biggest drugmakers, fell after a US health official said two of their best-selling treatments need closer safety reviews.
600129
Anglo-Swedish drugs giant AstraZeneca and British peer GlaxoSmithKline said Wednesday they had been approached by EU regulators as part of an antitrust probe into the pharmaceutical sector.
564304
WASHINGTON/LONDON  - An FDA review AstraZeneca  Plc's  under the name Coumadin.
113293
AstraZeneca was dealt a blow yesterday when an official from the US&#39;s drugs watchdog questioned whether one of its key products ought to be sold in the world&#39;s largest pharmaceuticals market.
371559
Drugs giant AstraZeneca today acknowledged that its anti-clotting drug Exanta is unlikely to win US approval any time soon and revealed a one-year delay with another new drug, Galida, for diabetes.
764957
SHARES in drugs giant AstraZeneca bounced back having slumped to a 19-month low earlier today as US regulators formally blocked the launch of its new blood-thinning treatment Exanta.
445999
The Food and Drug Administration (FDA) learned yesterday from AstraZeneca that a large clinical trial comparing Iressa (gefitinib) with placebo in patients with non-small cell lung cancer who had failed other courses of cancer therapy showed no survival
364661
AstraZeneca PLC&#39;s shares plunged 7.7 percent Friday after a study found that its new lung-cancer drug Iressa failed to improve survival rates among patients.
431734
Drug manufacturer AstraZeneca PLC announced Friday that trials of its new lung cancer drug found it didn't help patients live longer. Its shares dropped more than 8 percent.
247888
AstraZeneca will defend its new prescription drug Exanta before a federal panel today after new questions were raised about the safety and effectiveness of the stroke prevention medication.
45410
AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer in a major clinical trial, sending its shares down as much as 9.2 percent.
106113
Shares in AstraZeneca tumbled today after a key drug it has developed in the fight against strokes was provisionally rejected by US regulators.